Pulsenmore Ltd. - Ordinary Shares (PLSM)

On our desk, looking at the recent Form 424B3 filing, we note the registration of up to 3,125,000 ordinary shares for resale by a single selling shareholder. These shares stem from the June 2026 private placement comprising pre-funded warrants and ordinary warrants exercisable at $4.80. While the company will not receive proceeds from this resale unless warrants are exercised for cash, the sheer overhang relative to the 6,502,844 ordinary shares outstanding as of July 1, 2026, introduces notable potential dilution and near-term price volatility that we are factoring into our execution limits.

As a healthcare-focused hedge fund PM, the $7.5 million private placement with a single institutional buyer caught my attention. Pricing at $4.80 represents a premium to the Nasdaq Minimum Price and provides immediate capital earmarked for marketing, commercialization, and working capital. However, the Sharemaestro Evidence Rating scores PLSM at a cautious 35, highlighting a complete lack of confirmation across 12-week trend, activity pressure, and relative leadership metrics. We are treating this strictly as a watch-list turnaround play until technical stabilization materializes.

Reviewing the 2025 Form 20-F filed with the SEC, the financial realities of Pulsenmore Ltd. cannot be ignored. The company remains loss-making, reporting substantial net losses of NIS 58.6 million in 2023 and NIS 36.7 million in 2024, alongside executing a 1-for-8 reverse split of ordinary shares in late December 2025 prior to its January 2026 Nasdaq listing under 'PLSM'. Risk controls must account for these historical deficits and the operational risks outlined for an issuer headquartered in Omer, Israel.

In our clinical evaluation protocols, the core value proposition of Pulsenmore's technology centers on portable ultrasound solutions like the Pulsenmore ES, which holds regulatory clearances in the US, Europe, and Israel, and the Pulsenmore FC, which is in early commercialization in Israel. From a clinical adoption standpoint, shifting ultrasound to home and point-of-care settings has immense utility, but market penetration heavily depends on the company's ability to successfully execute its commercialization strategy amidst ongoing cash burn.

As a medical device analyst, I am tracking how effectively Pulsenmore allocates the net proceeds from the $7.5 million private placement closed around June 2026. With warrants immediately exercisable at $4.80 for a five-year term, the company has secured a runway, but the primary constraint remains its commercial uptake in international markets. Monitoring upcoming quarterly disclosures for tangible revenue growth from the Pulsenmore ES and FC lines will be vital to validate whether the current valuation can sustain further dilution.